Rigel Pharmaceuticals (RIGL) Change in Account Payables (2010 - 2026)

Rigel Pharmaceuticals' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$2.7 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 539.84% year-over-year to -$2.7 million; the TTM figure through Mar 2026 stood at $532000.0 (up 110.0% YoY), while the FY2025 annual figure was $3.9 million, up 201.29% from the prior year.
• Change in Account Payables was -$2.7 million for Q1 2026 at Rigel Pharmaceuticals, down from $3.3 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $4.8 million in Q4 2022 to a low of -$3.4 million in Q3 2025.
• Historically, Change in Account Payables has averaged $45058.8 across 5 years, with a median of -$476000.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Change in Account Payables soared 802.73% in 2025, then sank 539.84% in 2026.
• A 5-year view of Change in Account Payables shows it stood at $4.8 million in 2022, then plunged by 117.9% to -$857000.0 in 2023, then soared by 44.46% to -$476000.0 in 2024, then jumped by 802.73% to $3.3 million in 2025, then sank by 180.87% to -$2.7 million in 2026.
• The last three Change in Account Payables figures came in at -$2.7 million (Q1 2026), $3.3 million (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.